|Videos|April 26, 2023
CSCC: Escalating Therapy for High-risk Patients
Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shailender Bhatia, MD, discusses next steps for adjuvant therapy research in light of the phase 3 ADAM trial data and broader implications for Merkel cell carcinoma.
Shailender Bhatia, MD, discusses ADAM trial design, key efficacy and safety findings, and treatment implications in Merkel cell carcinoma.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
The FDA approved aminolevulinic acid hydrochloride plus PDT for the treatment of superficial basal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
iMMagine-1 vs CARTITUDE-1 MAIC Shows Comparable Efficacy, Improved Safety With Anito-Cel in Relapsed/Refractory Multiple Myeloma
3
Linvoseltamab Yields Deep, MRD-Negative Responses With Manageable Safety in High-Risk Smoldering Myeloma
4
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
5